Introduction: The treatment of spinal nerve root cysts is not uniform. In the past decades, microsurgical resection to preserve nervous tissue has been reported. We report on our microsurgical method and present the clinical results in relation to surgical outcome.
Material And Methods: Retrospective review of a consecutive series of patients who underwent surgical cyst closure from 2006 to 2010.
Results: Twelve patients, all female, with a total of 23 cysts underwent surgery for 20 symptomatic cysts. The mean age was 45 (range 13-75) years. Following treatment with this procedure, 95% of the cysts were closed and 5% had notably diminished at post-operative magnetic resonance imaging. Clinical improvement was seen in 67% of the patients; one improved temporarily, two remained unchanged and one had worsened at the last follow-up. The mean post-operative follow-up period was 11 (range 3-19) months. Clinical outcome was associated with none of the pre-operative parameters, i.e. pain-provoking postural position, cyst size, number of treated cysts, educational level or pre-operative sick leave.
Conclusion: We find that our surgical technique is suit-able for closure of spinal nerve root cysts; however, the clinical outcome after surgery was sub-optimal according to preoperative clinical judgement. Consequently, we have established a dedicated outpatient clinic that performs extensive pre-operative assessment and investigation of patients with symptomatic spinal nerve root cysts. We hereby hope to improve surgical outcome in the future.
Download full-text PDF |
Source |
---|
Pain Pract
February 2025
North American Spine & Pain, 404 Creek Crossing Blvd, Hainesport, 08056, New Jersey, USA.
Radiofrequency ablation (RFA) is an interventional procedure that has been used to treat chronic back pain for over 50 years; this unique case report demonstrates the effectiveness of pulsed radiofrequency ablation (PRFA) on the dorsal root ganglion (DRG) in the treatment of chronic radicular pain (Russo et al., 2021, J Pain Res, 14, 3897). The RFA provides pain relief by using thermal energy to disrupt peripheral nerves carrying nociceptive signals back to the central nervous system (Abd-Elsayed et al.
View Article and Find Full Text PDFMol Med
January 2025
Division of Spine Surgery, Department of Orthopedics, Nanfang Hospital, Southern Medical University, 1838 North Guangzhou Ave, Guangzhou, 510515, People's Republic of China.
Background: Neuropathic pain (NP) is a debilitating condition caused by lesion or dysfunction in the somatosensory nervous system. Accumulation of advanced oxidation protein products (AOPPs) is implicated in mechanical hyperalgesia. However, the effects of AOPPs on NP remain unclear.
View Article and Find Full Text PDFToxicon
January 2025
National Research Council of Italy, Institute of Biochemistry and Cell Biology, 00015, Monterotondo, RM, Italy. Electronic address:
Botulinum neurotoxin type A (BoNT/A) has expanded its therapeutic uses beyond neuromuscular disorders to include treatments for various pain syndromes and neurological conditions. Originally recognized for blocking acetylcholine release at neuromuscular junctions, BoNT/A's effects extend to both peripheral and central nervous systems. Its ability to undergo retrograde transport allows BoNT/A to modulate synaptic transmission and reduce pain centrally, influencing neurotransmitter systems beyond muscle control.
View Article and Find Full Text PDFPharmaceutics
January 2025
Laboratory of Pharmacology, School of Pharmacy, Nihon University, 7-7-1 Narashinodai, Funabashi 274-8555, Japan.
: We previously demonstrated that the intranasal administration of cell-penetrating Tat peptide-modified carrier, PEG-PCL-Tat, improves drug delivery to the central nervous system. This study aimed to evaluate the potential of the post-onset intranasal administration of -acetyl-L-cysteine (NAC) combined with PEG-PCL-Tat (NAC/PPT) for neuropathic pain. : Neuropathic pain was induced by partial sciatic nerve ligation (PSNL) in mice.
View Article and Find Full Text PDFJ Clin Med
January 2025
Research Group in Social and Nutritional Epidemiology, Pharmacoepidemiology and Public Health, Department of Preventive Medicine and Public Health, Food Sciences, Toxicology and Forensic Medicine, Faculty of Pharmacy, Universitat de València, Av. Vicent Andrés Estellés s/n, 46100 Burjassot, Spain.
The aim of this study was to evaluate the effects of spinal cord stimulation (SCS) on pain, neuropathic symptoms, and other health-related metrics in patients with chronic painful peripheral neuropathy (PN) from multiple etiologies. A prospective single center observational longitudinal cohort study assessed SCS efficacy from April 2023 to May 2024, with follow-ups at 2, 4, 6, and 12 months in 19 patients suffering from the painful polyneuropathy of diverse etiologies: diabetic (DPN), idiopathic (CIAP), chemotherapy-induced (CIPN), and others. Patients were implanted with a neurostimulator (WaveWriter Alpha, Boston Scientific Corporation, Valencia, CA, USA) and percutaneous leads targeting the lower limbs (T10-T11) and, if necessary, the upper limbs (C4-C7).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!